Rational Drug Design for Pseudomonas aeruginosa PqsA Enzyme: An in silico Guided Study to Block Biofilm Formation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shaker, Bilal | - |
dc.contributor.author | Ahmad, Sajjad | - |
dc.contributor.author | Thai,Thi Duc | - |
dc.contributor.author | Eyun, Seong-il | - |
dc.contributor.author | Na, Dokyun | - |
dc.date.available | 2020-11-20T01:40:07Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 2296-889X | - |
dc.identifier.issn | 2296-889X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/43509 | - |
dc.description.abstract | Pseudomonas aeruginosa is an opportunistic gram-negative bacterium implicated in acute and chronic nosocomial infections and a leading cause of patient mortality. Such infections occur owing to biofilm formation that confers multidrug resistance and enhanced pathogenesis to the bacterium. In this study, we used a rational drug design strategy to inhibit the quorum signaling system of P. aeruginosa by designing potent inhibitory lead molecules against anthranilate-CoA ligase enzyme encoded by the pqsA gene. This enzyme produces autoinducers for cell-to-cell communication, which result in biofilm formation, and thus plays a pivotal role in the virulence of P. aeruginosa. A library of potential drug molecules was prepared by performing ligand-based screening using an available set of enzyme inhibitors. Subsequently, structure-based virtual screening was performed to identify compounds showing the best binding conformation with the target enzyme and forming a stable complex. The two hit compounds interact with the binding site of the enzyme through multiple short-range hydrophilic and hydrophobic interactions. Molecular dynamic simulation and MM-PBSA/GBSA results to calculate the affinity and stability of the hit compounds with the PqsA enzyme further confirmed their strong interactions. The hit compounds might be useful in tackling the resistant phenotypes of this pathogen. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | Rational Drug Design for Pseudomonas aeruginosa PqsA Enzyme: An in silico Guided Study to Block Biofilm Formation | - |
dc.type | Article | - |
dc.identifier.doi | 10.3389/fmolb.2020.577316 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN MOLECULAR BIOSCIENCES, v.7 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000584762000001 | - |
dc.identifier.scopusid | 2-s2.0-85094848415 | - |
dc.citation.title | FRONTIERS IN MOLECULAR BIOSCIENCES | - |
dc.citation.volume | 7 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | multidrug resistance | - |
dc.subject.keywordAuthor | biofilm | - |
dc.subject.keywordAuthor | quorum sensing | - |
dc.subject.keywordAuthor | drug discovery | - |
dc.subject.keywordAuthor | structure-based virtual screening | - |
dc.subject.keywordPlus | TO-CELL COMMUNICATION | - |
dc.subject.keywordPlus | BURKHOLDERIA-PSEUDOMALLEI | - |
dc.subject.keywordPlus | VIRULENCE | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | SIMULATION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.